Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Gyre Therapeutics Inc GYRE

Healthcare Biotechnology
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GYRE)

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire 11 days ago

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

GlobeNewswire August 13, 2024

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

GlobeNewswire August 9, 2024

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

GlobeNewswire August 8, 2024

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

GlobeNewswire July 2, 2024

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

GlobeNewswire June 18, 2024

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

GlobeNewswire May 30, 2024

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

GlobeNewswire May 28, 2024

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024
View More News ››

Opinion & Analysis (NDAQ:GYRE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GYRE)

Be the first to post on this bullboard.

Xcyte Digital Corp.

Xcyte Digital Corp.

Xcyte Digital is a virtual event company focused on simplifying the event hosting industry and expanding event hosting ...
View More »